Recent studies have reported that targeting TRAIL is a promising anticancer therapy for prostate cancer, and harnessing TRAIL-induced apoptosis pathway for immunotherapy has attracted attention rapidly as a cancer treatment target (27, 28). This evidence concerns the gene TNFSF10 and cancer.